

TAS-103

Catalog No: tcsc3273



Available Sizes

Size: 5mg

Size: 10mg

Size: 50mg

Size: 100mg



Specifications

CAS No:

174634-08-3

Formula:

$C_{20}H_{19}N_3O_2$

Pathway:

Cell Cycle/DNA Damage

Target:

Topoisomerase

Purity / Grade:

>98%

Solubility:

10 mM in DMSO

Alternative Names:

BMS-247615

Observed Molecular Weight:

333.38


Product Description

TAS-103 is a dual inhibitor of DNA **topoisomerase I/II**, used for cancer research.

IC₅₀ & Target: Topoisomerase I/II^[1]

In Vitro: TAS-103 is a dual inhibitor of DNA topoisomerase I/II. TAS-103 (0.1-10 μ M) is active on CCRF-CEM cells, with an IC₅₀ value of 5 nM. TAS-103 (0.1 μ M) significantly increases levels of topo II α FITC immunofluorescence in individual CCRF-CEM cells^[1]. TAS-103 (0.01-1 μ M) is highly cytotoxic to Lewis lung carcinoma (LLC) cells, and Liposomal TAS-103 is almost as active as free TAS-103^[2]. TAS-103 inhibits the viability of HeLa cells, with an IC₅₀ of 40 nM. TAS-103 (10 μ M) disrupts signal recognition particle (SRP) complex formation, and induces destabilization of SRP14 and SRP19 and its eventual degradation^[3].

In Vivo: TAS-103 (30 mg/kg, i.v.) causes significant tumor growth suppression in mice bearing Lewis lung carcinoma (LLC) cells, without obvious body weight loss, and the liposomal TAS-103 is more active than free TAS-103^[2].



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!